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Abstract
Diseases of specific fibrocartilaginous joints are especially
common in women of reproductive age, suggesting that female
hormones contribute to their etiopathogenesis. Previously, we
showed that relaxin dose-dependently induces matrix
metalloproteinase (MMP) expression in isolated joint
fibrocartilaginous cells. Here we determined the effects of
relaxin with or without β-estradiol on the modulation of MMPs in
joint fibrocartilaginous explants, and assessed the contribution
of these proteinases to the loss of collagen and
glycosaminoglycan (GAG) in this tissue. Fibrocartilaginous
discs from temporomandibular joints of female rabbits were
cultured in medium alone or in medium containing relaxin (0.1
ng/ml) or β-estradiol (20 ng/ml) or relaxin plus β-estradiol.
Additional experiments were done in the presence of the MMP
inhibitor GM6001 or its control analog. After 48 hours of culture,
the medium was assayed for MMPs and the discs were analyzed
for collagen and GAG concentrations. Relaxin and β-estradiol
plus relaxin induced the MMPs collagenase-1 and stromelysin-1
in fibrocartilaginous explants – a finding similar to that which we
observed in pubic symphysis fibrocartilage, but not in articular
cartilage explants. The induction of these proteinases by relaxin
or β-estradiol plus relaxin was accompanied by a loss of GAGs
and collagen in joint fibrocartilage. None of the hormone
treatments altered the synthesis of GAGs, suggesting that the
loss of this matrix molecule probably resulted from increased
matrix degradation. Indeed, fibrocartilaginous explants cultured
in the presence of GM6001 showed an inhibition of relaxin-
induced and β-estradiol plus relaxin-induced collagenase and
stromelysin activities to control baseline levels that were
accompanied by the maintenance of collagen or GAG content
at control levels. These findings show for the first time that
relaxin has degradative effects on non-reproductive synovial
joint fibrocartilaginous tissue and provide evidence for a link
between relaxin, MMPs, and matrix degradation.
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Introduction
In certain sites in and around joints, ligaments and tendons
subjected to complex tensile and compressive loading spe-
cialize into fibrocartilaginous tissues [1-3] containing types
I and II collagens and cartilage-specific proteoglycans.
These tissues include specific regions of the metacar-
pophalangeal ligament and the deep flexor tendon, the tem-
poromandibular joint (TMJ) disc, and the pubic symphysis.
Within the pubic symphysis of several species, the repro-
ductive hormone relaxin induces matrix remodeling activity
during pregnancy and parturition, causing a marked
decrease in collagen content through partly characterized
mechanisms that transform this tissue into a ligamentous
structure [4-9]. The relaxin-mediated loss of matrix macro-
molecules in the pubic symphysis and other tissues is exac-
erbated by estrogen [4,7,8,10]. The relative contribution of
matrix synthesis and degradation to these relaxin-mediated
changes is not clear, although collagen loss through
increased proteolysis has been suggested [4], and studies
in relaxin-knockout mice have implicated increased colla-
genase activity [11].
To understand the potential basis for relaxin and estrogen's
modulation of the composition of fibrocartilaginous tissues,R1
ANOVA = analysis of variance; DMMB = 1,9-dimethylmethylene blue; GAG = glycosaminoglycan; FITC = fluorescin isothycyanate; MMP = matrix 
metalloproteinase; PBS = phosphate-buffered saline; TIMP = tissue inhibitor of metalloproteinase; TMJ = temporomandibular joint.
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Relaxin induced the expression of the matrix metalloprotei-
nases (MMPs) collagenase-1 (MMP-1) and stromelysin-1
(MMP-3) in a dose-dependent fashion but had little effect
on the expression of tissue inhibitor of metalloproteinase-1
(TIMP-1) or TIMP-2 [12]. In cells primed with β-estradiol,
however, the relaxin concentration required for maximal
induction of collagenase-1 and stromelysin-1 was 90–99%
lower than in unprimed cells. Notably, the MMP response
to relaxin was specific to fibrocartilaginous cells and was
not observed in TMJ synoviocytes. These findings suggest
that relaxin, by targeting fibrocartilage, might predispose
women to musculoskeletal diseases of fibrocartilaginous
joints.
One such disease is TMJ disorders, which affect some 11
million adults in the USA [13,14], predominantly women,
with a female : male ratio of 2:1 to 6:1 [14]. Unlike similar
diseases of other joints, TMJ disorders occur primarily in
women of reproductive age [14]. Given the gender and age
distribution of these disorders and the relaxin-induced loss
of matrix macromolecules in the pubic symphysis fibrocar-
tilage [4,6,7,9] and isolated TMJ fibrocartilaginous cells
[12], we have proposed that relaxin compromises the integ-
rity of fibrocartilaginous tissues by enhancing the degrada-
tion of their matrices directly through the induction of
specific MMPs. However, although relaxin causes a loss of
collagens and proteoglycans in reproductive organs [6,7]
and also increases MMP expression in specific tissues
[6,12,15-21], the induction of MMPs by relaxin has not
been demonstrated in joint fibrocartilaginous tissues or its
induction of MMPs has not been linked to the loss of matrix
macromolecules in any tissue.
In this study we determined the effects of relaxin with or
without β-estradiol on the modulation of MMPs, and
assessed the contribution of these proteinases to the
changes in collagen and glycosaminoglycan (GAG) con-
tent in fibrocartilaginous disc explants. Our findings are
consistent with the hypothesis that relaxin-mediated induc-
tion of MMPs is associated with the loss of matrix macro-
molecules that could compromise tissue function and
biomechanics and might lead to joint disease.
Materials and methods
Materials
Twenty-week-old female New Zealand white rabbits were
obtained from Nita Bell Laboratories (Hayward, California,
USA). Ketamine hydrochloride was from Parke Davis (Mor-
ris Plains, New Jersey, USA), and xylazine was from Rugby
Lab (Rockville Center, New York, USA). Lactalbumin hydro-
lysate, α-casein, β-estradiol-17-valerate, pepsin, papain,
chondroitin sulfate A sodium from bovine trachea, Safranin-
O, Fast Green, cetylpyridinium chloride, and other reagents
were from Sigma (St Louis, Missouri, USA). 1,9-Dimethyl-
methylene blue (DMMB) was from Molecular Probes
(Eugene, Oregon, USA), and 35S was from Amersham
(Arlington Heights, IL, USA). Protein assay kits, gelatin (EIA
grade), and nitrocellulose membrane were from Bio-Rad
(Hercules, California). α-Minimal essential medium, trypsin,
penicillin–streptomycin, and Fungizone® were from Gibco
(Grand Island, New York, USA). All other standard chemi-
cals were from Sigma or Fisher Scientific (Pittsburg, Penn-
sylvania, USA).
Rabbit anti-human collagenase-1 polyclonal antibody and
rabbit anti-mouse stromelysin-1 monoclonal antibody,
horseradish peroxidase-conjugated secondary antibodies,
and the MMP inhibitor GM6001 and its control analog
were from Chemicon International (Temecula, California,
USA). Rabbit anti-human-TIMP-1 antibody that cross-
reacts with the rabbit inhibitor [12] was from Triple Point
Biologics (Forest Grove, Oregon, USA). Enhanced chemi-
luminescence reagent for western blotting was from Amer-
sham International (Little Chalfont, Bucks., UK). Sircol
collagen assay kit was from Accurate Chemical and Scien-
tific Corporation (Westbury, New York, USA), and fluores-
cein isothiocyanate (FITC)-labelled collagen was from
Chondrex (Seattle, Washington, USA). Recombinant
human relaxin was kindly provided by Connetics Corpora-
tion (Palo Alto, California, USA).
Retrieval and culturing of TMJ discs, pubic symphysis, 
and articular cartilage
All procedures on rabbits were approved by the Committee
on Animal Research of the University of California, San
Francisco, and conducted in accord with accepted stand-
ards of humane animal care. Rabbits were anesthetized
with ketamine hydrochloride (40 mg/kg) and xylazine (3–5
mg/kg), and the TMJ discs were harvested bilaterally under
sterile conditions and immediately placed in calcium-free
and magnesium-free phosphate-buffered saline (PBS) con-
taining antibiotics (100 U/ml penicillin, 100 mg/ml strepto-
mycin, and 100 U/ml Fungizone). After removal of the
synovium under a dissecting microscope, each disc was
washed three times in PBS and bisected longitudinally
such that four samples from each rabbit were available
(three for hormone treatments and one for control). The
hemisections were weighed, placed in wells of a 24-well
culture plate, covered with 1 ml of serum-free medium (phe-
nol-free α-minimal essential medium with 0.2% lactalbumin
hydrolysate, glutamine, nonessential amino acids, 100 U/ml
penicillin, and 100 mg/ml streptomycin) with or without hor-
mones, and cultured at 37°C in air containing 5% CO2.
For determination of MMPs and GAG staining, 32
hemisections from eight rabbits were exposed to medium
alone, β-estradiol (20 ng/ml), relaxin (0.1 ng/ml), or both
hormones at the same doses for 48 hours. The conditioned
medium was collected and stored for MMP assays, and the
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contribution of relaxin-induced MMPs to the loss of colla-
gen and GAGs, 24 hemisections from six rabbits were cul-
tured with the MMP inhibitor GM6001 or its control analog
2 hours before and during the hormone treatments. The
inhibitor was used at 10 µM, because this concentration
was shown to inhibit collagenase activity induced by 0.1
ng/ml relaxin in dose–response experiments to baseline
levels. The conditioned medium was collected and stored
at -70°C for total protein and MMP assays. The discs were
dried in a SpeedVac®, weighed, digested, and used for the
determination of GAG and collagen content.
To determine whether the observed induction of colla-
genase by relaxin is specific to fibrocartilage, experiments
were performed with pubic symphysis fibrocartilage, which
is a known target site for β-estradiol and relaxin as a posi-
tive control, and with articular cartilage from the knee. For
retrieval of articular cartilage, the joint was shaved, the
articular surfaces were exposed, and the cartilage was
scraped from the articular surfaces of the femur and tibia
and incubated in PBS with antibiotic as described above.
Similarly, the pubic bones and symphyseal areas were
exposed under sterile conditions and the pubic symphysis
(fibrocartilaginous tissues between the pubic bones) was
dissected, removed, and incubated in PBS with antibiotics.
The tissues were weighed, placed in wells of a 24-well cul-
ture plate, and studied as described above.
Western blotting
Hormone-induced changes in collagenase-1, stromelysin-
1, and TIMP-1 were determined by western blotting. Disc-
conditioned medium was mixed with 4 × sample buffer and
subjected to SDS–polyacrylamide-gel electrophoresis with
10% or 18% gels. Equal amounts of protein (determined
with a bicinchoninic acid protein assay kit) were loaded in
each lane. The proteins were transferred to nitrocellulose
membranes, which were blocked, washed, and incubated
for 1 hour with antibodies against TIMP-1 (1:250 dilution),
collagenase-1 (1:250 dilution in Tris-buffered saline), or
stromelysin-1 (1:500 dilution). The membranes were then
washed, incubated with horseradish peroxidase-conju-
gated goat anti-rabbit antibody (1:1000 dilution), and
washed again. Bands were revealed by incubation with
enhanced chemiluminescence reagent and exposure to
radiographic film. The bands for TIMP-1 western blots were
quantified by videodensitometry as described [22]. Condi-
tioned medium from pubic symphysis and articular cartilage
explants was similarly subjected to western blot analysis for
collagenase-1 and stromelysin-1.
Substrate zymography
Enzyme activities were quantified by substrate zymography
of conditioned media from 32 hemisections (mean wet
weight 13 ± 9 mg). The samples were standardized by total
protein and subjected to SDS–polyacrylamide-gel electro-
phoresis with 10% gels containing 2 mg/ml gelatin or
casein at 15°C as described [22]. The gels were washed
in 2.5% Triton X-100 for 30 min with one change of wash
buffer, incubated at 37°C for 60–72 hours in incubation
buffer (50 mM Tris-HCl buffer pH 8, 5 mM CaCl2, 0.02%
NaN3), stained with 5% Coomassie blue, and destained in
10% acetic acid and 40% methanol until proteinase bands
were clearly visible. Images of the gels were captured with
a charge-coupled device camera and NIH image software.
The levels of 53/58 kDa gelatinolytic and 51/54 kDa casei-
nolytic enzymes and their low-molecular-mass activated
forms were quantified by videodensitometry [22]. The sub-
strate zymograms rather than western blots were used to
quantify hormone-mediated increases in proteinase levels
because zymograms are more sensitive, often display both
pro-forms and active forms of proteinases, show a greater
linear range of densitometric values and have good repro-
ducibility that together enable a reliable quantification of
the enzymes from these gels [23-25]. In addition, gelatin
zymograms selectively detect proteinase activity at 53/58
kDa and at 43 kDa attributable primarily to collagenase
rather than stromelysin because gelatin is a poor substrate
for stromelysin [25,26].
Histochemical staining and quantification of GAGs
To assess changes in GAG levels, the discs were washed
three times in PBS, frozen in OCT compound, and sec-
tioned with a cryostat. The section were defrosted for 30
min, fixed for 10 min in methanol, air-dried for 15 min,
stained with 1% Fast Green solution for 3 min, placed in
1% acetic acid for 1 min, stained with 2% Safranin-O for 2
min, dehydrated through successive ethanol and xylene
washes, and mounted with coverslips. Ten sections of each
hemisection were analyzed by an examiner blinded to the
hormone treatment. The stained discs were videodigitized
and analyzed with a software program that automatically
outlined the total and Safranin-O-stained areas with thresh-
old settings (Photoshop 4.0; Adobe, San Jose, California,
USA). These areas were then quantified with NIH Image
1.62, and the percentage of disc staining positive for
GAGs was calculated from the ratio of the stained area to
the total area in each section. The average of the 10 values
for each half disc was used for analysis.
Determination of GAG synthesis by 35S radiolabeling
To quantify GAG biosynthesis, 32 disc hemisections
(mean weight 14 ± 4 mg) were incubated at 37°C for 6
hours in 1 ml of phenol-free and serum-free medium with or
without hormones and 165 kBq (0.0044 mCi) of 35S as
described [27]. The discs were washed three times with
medium containing 1 mg/ml sodium sulfate and digested
for 24 hours with 20 U/ml papain. The digest (500 µl) was
incubated for 30 min with 100 µl of 5% cetyl pyridiuium
chloride in 0.3 M potassium chloride at room temperature
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g for 20 min), the supernatant was removed and the precip-
itate was dissolved in 600 µl of concentrated formic acid by
heating to 70°C for 10 min. Aliquots (20 µl) of this solution
were added to 3 ml of scintillation fluid and subjected to liq-
uid scintillation counting. The radioactivity (counts/min)
was standardized to the total dry disc weight.
Quantification of GAGs and collagen
Each disc hemisection was digested in 600 µl of 3 mg/ml
pepsin in 0.05 M acetic acid and incubated at 37°C for 18–
20 hours in a dry bath. DMMB binding assays for GAGs,
and Sircol assays for collagen content, were performed in
triplicate on 24 disc hemisections. The DMMB reagent was
prepared as described [28]. Pepsin digests (200 µl) from
each treatment group (GM6001 or analog control) were
mixed with 1 ml of DMMB reagent, and absorbance at 525
nm was determined with a spectrophotometer. The GAG
concentration (µg/ml) was determined by comparing the
absorbance of the sample against a standard curve pre-
pared from bovine chondroitin sulfate A, and the disc GAG
content was standardized to the total dry tissue weight.
For the collagen assay, 200 µl of pepsin digest was mixed
with 1 ml of Sircol dye reagent, incubated for 30 min at
room temperature, and centrifuged at 10,000 g to separate
the unbound dye from the collagen-bound dye. After
removal of the unbound dye, 1 ml of the alkali reagent was
added to the collagen–dye complex and vortex-mixed to
dissolve the collagen-bound dye completely. Aliquots (200
µl) were transferred to the 96-well plates, and absorbance
at 550 nm was determined with a microtiter plate reader
(Molecular Devices, Sunnyvale, California, USA). The colla-
gen concentration (µg/ml) was determined against a colla-
gen standard curve, and the disc collagen content was
standardized to the total disc dry weight.
Quantification of collagenase activity
Collagenase activity in conditioned medium from discs cul-
tured with GM6001 or control analog was assessed by
FITC–collagen assay. A 96-well plate was coated with
FITC–collagen (10 µg per well) overnight at 4°C and
washed twice with PBS. Disc-conditioned medium (100 µl)
was added to the wells, and the plate was incubated at
35°C for 1 hour. As a reference, 100 µl of blank medium
containing 3000 ng of bacterial collagenase was added to
one set of wells for complete digestion of FITC–collagen.
After incubation, 90 µl from each well was transferred to
another 96-well plate, and the fluorescence intensity of
degraded FITC–collagen products was determined with a
microplate spectrofluorometer (Spectramax Gemini XS;
Molecular Devices) with excitation at 494 nm and emission
at 518 nm. The data were converted to relative fluores-
cence units of collagenase activity as described by the
manufacturer and standardized to the dry weight of each
half disc. The fold differences in collagenase activity in
medium from control and hormone-treated discs were
determined for each experiment. All assays were performed
in duplicate.
Statistical analysis
Because of inherent variability in matrix content and protei-
nase activity in discs from different rabbits, three disc
hemisections from each rabbit were treated with hormones
and one served as control. MMP levels and the GAG and
collagen content in each hormone-treated disc hemisec-
tion were standardized to the values of the control hemisec-
tion within each animal and the fold changes were plotted
as histograms. The statistical significance of differences
was determined by single-factorial analysis of variance
(ANOVA). Intergroup differences were analyzed by Fisher's
multiple comparisons test; P < 0.05 was considered statis-
tically significant. Values are expressed as means ± SD.
Results
Relaxin and β-estradiol induce collagenase-1 and 
stromelysin-1 in TMJ disc explants
Explanted discs constitutively expressed collagenase-1
(MMP-1) (Fig. 1a, lane 1), and the expression of this protei-
nase was increased by exposure to relaxin alone or to β-
estradiol plus relaxin (Fig. 1a, lanes 3 and 4). Gelatin sub-
strate zymograms confirmed the induction of 53/58 kDa
proteinase by these hormones and, because this assay is
more sensitive than western blots, showed an additional 43
kDa gelatinolytic enzyme (Fig. 1b). Because the gelatino-
lytic enzymes were inhibited by 1,10-phenanthroline (Fig.
1b, lane 5), these proteinases were characterized as
MMPs, most probably procollagenase-1 and active colla-
genase-1. Western blots with conditioned medium from a
disc explant exposed to relaxin showed that the 53/58 kDa
and 43 kDa activities corresponded to procollagenase-1
and collagenase-1, respectively (Fig. 1b, lane 6). Protein-
ase expression was about 1.7-fold higher in relaxin-treated
and β-estradiol plus relaxin-treated discs than in control cul-
tures (P < 0.05) and was not potentiated by β-estradiol
(Fig. 1c).
Because the expression of stromelysin and collagenase is
often coordinately regulated [29], we assessed stromelysin
expression. Western blots showed that all three hormone
treatments induced stromelysin-1 (MMP-3) (Fig. 1d).
Casein substrate zymograms demonstrated a 51/54 kDa
caseinolytic proteinase (Fig. 1e, lanes 1–4) that was inhib-
ited by 1,10-phenanthroline (Fig. 1e, lane 5), indicating a
metalloprotease. This characterization was confirmed by
western blotting (Fig. 1e, lane 6). Proteinase expression in
relaxin-treated cultures was double that in control cultures
(P < 0.05) and was not potentiated by β-estradiol.
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fibrocartilage but not in articular cartilage
In pubic symphysis fibrocartilage, which is a known target
site for β-estradiol and relaxin, β-estradiol caused slight
increases in collagenase-1, while relaxin alone or in combi-
nation with β-estradiol induced a substantially greater
expression of collagenase-1 relative to untreated discs
(Fig. 2a). Relaxin also increased stromelysin-1 levels in
pubic symphysis fibrocartilage. However, β-estradiol alone
or in conjunction with relaxin produced substantially greater
increases in stromelysin-1 levels than relaxin alone. In knee
articular cartilage, although β-estradiol induced colla-
genase-1 and stromelysin-1, neither relaxin nor β-estradiol
plus relaxin increased the expression of these proteinases
over control levels (Fig. 2b,2d). Indeed, relaxin alone
seemed to inhibit stromelysin-1 expression in articular
cartilage.
Loss of GAGs parallels the induction of MMPs by relaxin 
but not by β-estradiol
Because all hormone treatments induced stromelysin-1
expression in explanted discs, we assessed the level of a
known substrate, proteoglycans, in Safranin-O-stained
sections. The GAG-positive area was larger in control discs
(30.1 ± 2.8% of total disc area) and discs treated with β-
estradiol (29.7 ± 4.7%) than in those treated with relaxin
(19.2 ± 3.3%) or β-estradiol plus relaxin (16.9 ± 2.7%)
(Fig. 3a). These findings reflect statistically significant dif-
ferences (P < 0.01, ANOVA) in GAG staining between
control discs and those treated with relaxin (P < 0.05,
Fisher's test) or β-estradiol plus relaxin (P < 0.01). Similarly,
the GAG-positive area was significantly smaller (P < 0.04,
ANOVA) in discs treated with relaxin (P < 0.05, Fisher's
test) or β-estradiol plus relaxin (P < 0.05) than in those
treated with β-estradiol alone.
β-Estradiol induces TIMP-1
To determine why GAG loss did not increase in parallel
with stromelysin expression in explants treated with β-estra-
diol alone, we assessed GAG synthesis and TIMP-1
expression. Except for a significantly lower GAG synthesis
in discs exposed to β-estradiol plus relaxin than in those
exposed to β-estradiol alone (P < 0.05), differences
between the other groups were not significant (Fig. 3b). β-
Estradiol caused a significant (P < 0.01) twofold induction
in TIMP-1 expression over controls (Fig. 3c,3d). However,
neither relaxin alone nor β-estradiol plus relaxin modulated
any changes in TIMP-1 expression in the disc explants.
Figure 1
Relaxin induces collagenase-1 and stromelysin-1 in fibrocartilaginous explants from temporomandibular joint. Disc hemisections were exposed for 
48 hours to basal control medium (Ct), β-estradiol (Es, 20 ng/ml), or relaxin (R, 0.1 ng/ml) or to β-estradiol plus relaxin (Es+R). Conditioned medium, 
standardized by tissue weight, was subjected to SDS–polyacrylamide-gel electrophoresis and transferred to membranes for western immunoblots 
for collagenase-1 (a) or stromelysin-1 (d) or assayed in gels containing gelatin (b) or α-casein (e). Images of the substrate gels were digitized, and 
the 53/58 kDa and 43 kDa gelatinase activities (collagenase and active collagenase, respectively) (c) and the 51/54 kDa caseinolytic activity 
(stromelysin) (f) were quantified by videodensitometry. The samples used in lane 6 of panels (b) and (e) are positive controls for collagenase-1 and 
stromelysin-1. P, gels incubated in buffer containing the metalloproteinase inhibitor 1,10-phenanthroline; Cl-1, collagenase-1; ACl-1, active colla-
genase-1; Sl-1, stromelysin-1; α-Cl, anti-collagenase-1 antibody; α-Sl, anti-stromelysin-1 antibody. * P < 0.05.
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Relaxin induces collagenase-1 and stromelysin-1 in pubic symphysis fibrocartilage but not in articular cartilage. Pubic symphysis fibrocartilage or 
knee articular cartilage explants were exposed for 48 hours to basal control medium (Ct), β-estradiol (Es, 20 ng/ml), or relaxin (R, 0.1 ng/ml) or to β-
estradiol plus relaxin (Es+R). Conditioned medium, standardized by tissue weight, was subjected to western blotting for collagenase-1 (a, b) or 
stromelysin-1 (c, d). Cl-1, collagenase-1; Sl-1, stromelysin-1.
Figure 3
Induction of matrix metalloproteinases by relaxin but not by estrogen is accompanied by loss of glycosaminoglycans (GAGs)r l i  t t y estr en is acco panied by loss of glycosaminoglycans (GAGs). (a) Disc explants were 
cultured for 48 hours in basal control medium (Ct), β-estradiol (Es, 20 ng/ml), or relaxin (R, 0.1 ng/ml) or in β-estradiol plus relaxin (Es+R), then sec-
tioned and stained with Safranin-O for GAGs. The percentage area staining positive for GAGs was determined histomorphometrically and plotted. 
Values are means ± SD. (b) Hormone-mediated changes in GAG synthesis were assessed by 35S-labeling of fibrocartilaginous disc explants. The 
explants were washed and digested with papain, and the radioactivity was measured. Fold changes (means ± SD) in 35S incorporated into the 
explants incubated with hormones relative to that in control discs were determined and plotted. (c) To evaluate the modulation of tissue inhibitor of 
metalloproteinases-1 (TIMP-1) by hormones, the conditioned medium, standardized dry tissue weight (mg), was resolved electrophoretically and 
transferred to nitrocellulose membranes, and the membranes were probed with anti-TIMP-1 antibody. (d) The bands were quantified by videodensit-
ometry, and the fold induction (mean ± SD) of TIMP-1 by various hormone treatments relative to untreated control explants was plotted. T-1, TIMP-1. 
* P < 0.05, ** P < 0.01 by Fisher's test.
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loss of GAGs
To establish an association between the increased MMP
activity and the loss of GAGs in explants treated with
relaxin or β-estradiol plus relaxin, we cultured the explants
with the MMP inhibitor GM6001 or its control analog.
Western blot analysis showed a higher expression of
stromelysin-1 in hormone-treated than untreated disc
explants in the presence of GM6001 or its control analog
(data not shown). However, zymography showed increased
51/54 kDa caseinolytic activity (stromelysin-1) only in hor-
mone-treated explants incubated with the control analog
(Fig. 4a), and not in those incubated with GM6001 (Fig.
4b).
DMMB assays showed that hormone treatments in the
presence of control analog decreased the GAG content (P
< 0.0001, ANOVA), which was 30% lower in relaxin-
treated explants (P < 0.001, Fisher's test) and 40% lower
in those treated with β-estradiol plus relaxin (P < 0.001)
than in untreated explants (Fig. 4c). Similarly, the GAG con-
tent was lower (P < 0.0001, ANOVA) in discs treated with
relaxin (P < 0.05, Fisher's test) or β-estradiol plus relaxin (P
< 0.001) than in those treated with β-estradiol alone. In the
presence of GM6001, however, hormone treatments did
not affect the GAG content (Fig. 4d).
Relaxin-induced collagenase activity contributes to loss 
of disc collagen
All three hormone treatments increased the expression of
procollagenase-1 in the presence of GM6001 or its control
analog similarly to that shown in Fig. 1a,1b,1c. However, as
shown by FITC-collagen degradation assays, collagenase
activity was significantly increased only by relaxin or β-
estradiol plus relaxin in the presence of the control analog
(Fig. 5a). In discs incubated with GM6001, hormone-
induced collagenase activity was inhibited to control levels
(Fig. 5b). Conversely, Sircol assays showed the collagen
content was significantly decreased (P < 0.0001, ANOVA)
only in the presence of the control analog and only by
relaxin (40% of control and β-estradiol alone; P < 0.0001,
Fisher's test) or β-estradiol plus relaxin (60% versus control
and β-estradiol alone; P < 0.0001) (Fig. 5c). In the pres-
ence of GM6001, hormone treatments did not affect colla-
gen content (Fig. 5d).
Discussion
This study shows that relaxin induced the expression of col-
lagenase-1 and stromelysin-1 in rabbit TMJ disc explants,
accompanied by a loss of GAGs and collagen, but did not
affect GAG synthesis. In explants cultured with the MMP
inhibitor GM6001, collagenase-1 and stromelysin-1 activi-
ties in hormone-treated discs were inhibited to baseline lev-
Figure 4
Inhibition of matrix metalloproteinase (MMP) activity prevents relaxin-mediated loss of glycosaminoglycans (GAGs). Conditioned medium from disc 
hemisections incubated with β-estradiol (Es), relaxin (R), or β-estradiol plus relaxin (Es+R) in the presence of the MMP inhibitor GM6001 or its con-
trol analog was assayed by casein substrate zymograms (a, b). Disc digests from these experiments were assayed for GAGs with the 1,9-dimethyl-
methylene blue assay, and the results were standardized to tissue dry weight (mg). Fold changes in GAG concentration (mean ± SD) were 
calculated and plotted (c, d). The untreated control (Ct) discs used in all experiments were exposed to control analog only. * P < 0.05, ** P < 0.01, 
*** P < 0.001 by Fisher's test.
Arthritis Research & Therapy    Vol 7 No 1    Naqvi et al.
R8els, and collagen and GAG content were maintained at
control levels. These findings show that relaxin has degra-
dative effects on nonreproductive synovial joint fibrocarti-
laginous tissue and provide evidence that increases in
MMP activity mediated by relaxin and β-estradiol plus
relaxin contribute directly to the loss of disc collagen and
GAGs. The lack of effect on GAG synthesis further
validates the importance of the degradative component of
the remodeling cycle in relaxin's modulation of matrix loss in
fibrocartilage.
Because the MMP inhibitor used in our studies is not spe-
cific for collagenase-1 and stromelysin-1, the hormone-
induced loss of collagen and GAGs cannot be specifically
linked to those two proteinases. Rather, our findings impli-
cate MMPs in general in this response. However, because
GM6001 has a low dissociation constant for both colla-
genase-1 and stromelysin-1 [30], and their induction by
relaxin was accompanied by a loss of their matrix sub-
strates, collagenase-1 and stromelysin-1 are probably
involved in the relaxin-mediated loss of collagen and GAGs,
respectively.
In contrast to the results obtained with relaxin and β-estra-
diol plus relaxin, the induction of collagenase-1 and strome-
lysin-1 by β-estradiol alone was not accompanied by
changes in GAG or collagen content within the disc. How
can we explain this apparent discrepancy? β-Estradiol had
little effect on GAG synthesis, as measured by 35S incorpo-
ration, but it produced a statistically significant increase in
TIMP-1 expression that could have counteracted any
increases in degradative activity due to increased expres-
sion of collagenase-1 and stromelysin-1. Indeed, the results
of the collagen degradation assay lend credence to this
hypothesis. These findings imply that relaxin and β-estradiol
selectively contribute to the degeneration of fibrocartilagi-
nous tissue by differentially modulating MMP expression,
matrix synthesis, and net matrix content.
Figure 5
Relaxin-induced collagenase activity contributes to loss of disc collagen. Conditioned medium from disc incubated with control medium (Ct), β-
estradiol (Es), relaxin (R), or β-estradiol plus relaxin (Es+R) in the presence of the matrix metalloproteinase inhibitor GM6001 or its control analog 
was subjected to fluorescein isothiocyanate-labelled collagen degradation assay. The collagenase activity (relative fluorescence units [RFU]/ml) was 
standardized by the dry weight of the tissue (mg), and fold changes (means ± SD) were plotted (a, b). Disc digests from these experiments were 
assayed for collagen with the Sircol assay, and the results were standardized to tissue dry weight (mg). Fold changes in collagen concentration 
(means ± SD) were calculated and plotted (c, d). The untreated control (Ct) discs used in all experiments were exposed to control analog only. ** P 
< 0.01, *** P < 0.0001 by Fisher's test.
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cartilaginous explants and the pubic symphysis fibrocarti-
lage to relaxin are reflected not only by the relaxin's
induction of collagenase but also by the comparable loss of
collagen on the exposure of these tissues to the hormone
[4,9]. Thus, the extent of collagen loss in fibrocartilaginous
disc explants exposed to relaxin (40%) or β-estradiol plus
relaxin (60%) was similar to that in the pubic symphysis of
unprimed and β-estradiol-primed ovariectomized nonpreg-
nant rats (64 ± 4% and 68 ± 6%, respectively) [4]. Simi-
larly, in pregnant ovariectomized rats, relaxin decreased
collagen to 39% of the levels in nonpregnant animals [9].
Additionally, β-estradiol alone had minimal effects on the
collagen content of the fibrocartilaginous TMJ disc, which
is also similar to observations on the pubic symphysis [4,9].
Thus, relaxin with or without β-estradiol, but not β-estradiol
alone, has a potent effect on the amount of collagen in
fibrocartilaginous tissues from different sites, including the
pubic symphysis and synovial joints. These findings also
suggest that in fibrocartilaginous tissues, including the TMJ
disc and possibly the pubic symphysis, relaxin decreases
collagen and GAG content primarily by inducing MMP
expression.
The response of articular cartilage to relaxin or β-estradiol
plus relaxin was substantially different from that of the TMJ
disc and pubic symphysis fibrocartilages. Although the rea-
sons for these differences remain to be determined, it is
well accepted that articular cartilage is a cartilaginous
tissue containing chondrocytic cells, whereas fibrocartilage
is a heterogenous tissue composed of cartilage and fibrous
tissue that contains cells of fibroblastic, chondrocytic, and
fibrochondocytic phenotypes. It is plausible that of these
cells, the fibroblastic and/or fibrochondrocytic cells found
in fibrocartilage, rather than the chondrocytic cells, are
those that produce the observed responses to relaxin and
β-estradiol plus relaxin. Indeed, previous findings on both
dermal fibroblasts showing a potent induction of MMP-1
[18] and on articular chondrocytes that show minimal
modulation of total collagen synthesis by relaxin [31] lend
credence to this hypothesis. Additional studies are indi-
cated to address the mechanistic basis for the differences
in responsiveness of fibrocartilaginous versus cartilaginous
cells to relaxin.
Our findings are consistent with emerging data suggesting
that the mechanisms for the loss of matrix macromolecules
caused by relaxin are tissue-specific [32]. Thus, for exam-
ple whereas relaxin increases collagenase-1 expression in
TMJ disc and pubic symphyseal [6] fibrocartilages, it had
minimal effects on its expression in articular cartilage
explants. In monolayer articular or multilayer growth plate
rabbit chondrocytes, relaxin produces no net change in col-
lagen synthesis and no alterations in type II collagen mRNA
levels, but increases the expression of types I and III colla-
gen mRNA, thereby amplifying the dedifferentiation proc-
ess [31]. In contrast, relaxin downregulates collagen
expression by up to 40% and induces collagenase expres-
sion in cultured dermal fibroblasts [18]. As in our study,
relaxin increases collagenase activity in human cervical
stromal cells; however, in contrast to our findings, it also
increases GAG synthesis [15,16].
MMPs contribute substantially to tissue degeneration in
inflammatory joint diseases, including rheumatoid arthritis
and osteoarthritis [33-35]. Our findings show that relaxin
directly modulates MMP expression and probably causes
matrix loss in fibrocartilaginous tissues from a synovial joint.
Although the effects of relaxin on loss of matrix macromol-
ecules, particularly collagen, have been demonstrated in
the fibrocartilaginous pubic symphysis [4-7], this is the first
study to demonstrate a similar targeting of fibrocartilagi-
nous tissues from the synovial TMJ, and may implicate this
hormone in the pathogenesis of TMJ disease in a subset of
women with these disorders. Because even subtle altera-
tions in collagen and GAG composition can affect the
structural properties and the ability of joint tissues to func-
tion normally, this modulation of MMPs and resulting matrix
loss in the fibrocartilaginous TMJ disc by relaxin might
explain the distinct age and gender distribution of TMJ dis-
eases. Furthermore, these findings have potential physio-
logic relevance because the induction of collagenase-1
and stromelysin-1 and the loss of collagen and GAGs
occurred at concentrations of relaxin found systemically in
cycling women [36-38]. Although the ability of systemic
relaxin to access the TMJ and reach the avascular disc
remains to be determined, our recent findings in vivo show-
ing relaxin-mediated decreases in GAG concentration in
the TMJ discs of ovariectomized rabbits suggest that this
systemic hormone can indeed access the TMJ disc and
contribute to its degradation [39].
Conclusions
Relaxin causes the targeted induction of collagenase-1 and
stromelysin-1 in synovial joint and pubic symphysis fibro-
cartilages but not in articular cartilage. This induction of
MMPs in joint fibrocartilage is accompanied by a loss of
collagen and GAGs that is prevented by an MMP inhibitor,
suggesting a link between relaxin, MMPs, and matrix degra-
dation. These studies provide the first evidence that relaxin
contributes to the degradative remodeling of joint fibrocar-
tilage and that there is an association between relaxin-
induced MMPs and matrix loss; they also suggest a poten-
tial mechanism of action of relaxin in contributing to TMJ
diseases in a subset of women with these disorders.
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